ea0094p125 | RET | SFEBES2023
Stoneham Sara
, A Corley Elizabeth
, Ross Emma
, Gevers Evelien
, Newbold Kate
, Beale Tim
, Wong Kee
, Brain Caroline
, Albanese Assunte
, Butler Colin
, Abdel-Aziz Tarek
, Proctor Ian
, R Kurzawinsky Tom
, V Marshall Lynley
Background and Demographics: Medullary thyroid carcinoma (MTC), in the context of Multiple Endocrine Neoplasia type 2 (MEN2), is caused by mutations in the RET proto-oncogene. For children with MEN2, both 2A and 2B subtypes, and advanced MTC, the RET tyrosine kinase (TK) pathway is a target for treatment with selpercatinib, a selective RET TK inhibitor (TKI). In the United Kingdom, 7 paediatric patients have been receiving named -patient, compassionate access ...